Cerebras Systems heads into the final week of September with short sellers adding positions steadily, even as the stock trades 49% below the Street's mean price target.
Short interest has climbed roughly 28% over the past six weeks, rising from about 10.2 million shares in late August to 14.1 million now, a 9.3% gain on the week alone. The 30-day increase is 37%. There is no free-float percentage available from the snapshot, but the absolute build is unambiguous: bears have been adding through the stock's recovery and into its recent pullback. The ORTEX short score has drifted higher alongside, reaching 67.5, its highest reading of the past two weeks. The direction of travel is clear even if the size of the short relative to float cannot be pinned down precisely.
The lending market tells a more nuanced story. Borrow availability has tightened to roughly 47%, meaning just under one share remains available for every two already lent out. That is not extreme by historical standards: the 52-week minimum availability reached zero, and availability spent much of late August below 10%. Cost to borrow has actually fallen sharply, down 38% on the week and 52% over the past month, now at a low 0.63%. The combination of growing short interest and falling borrow costs suggests new shorts are finding supply without difficulty. There is no squeeze pressure visible in the lending data right now. Options positioning is similarly unremarkable: the put/call ratio of 0.97 sits just below its 20-day average of 0.98, effectively neutral.
The gap between where the stock trades and where analysts think it should trade is the most striking number on the page. CBRS closed at $194.95 on September 29, down 8.2% on the week and having given back part of a strong month. The mean analyst price target is $291.64, implying roughly 49% upside from current levels. The analyst community has been consistently bullish: recent moves from Rosenblatt, Needham, UBS and Morgan Stanley all maintained or raised targets after the last earnings print in August, with UBS lifting its target to $330 and Morgan Stanley nudging to $279. The lone dissent in recent activity is a Hold from Freedom Capital Markets at $209. The bull case rests on Cerebras's wafer-scale architecture, a claimed 30x tokens-per-second edge over GPUs for inference, and a $25 billion remaining performance obligation largely tied to OpenAI. Bears point squarely at customer concentration: OpenAI, G42, MBZUAI and AWS together account for the bulk of revenue, and any shift in those relationships carries outsized risk. The PE sits at 235x, the EV/EBITDA at 15x, both compressing over the past month as the stock recovered.
The ownership register adds another layer of interest. Lior Susan, who filed a Schedule 13D in May, is on the register as an activist holder. The most recent amendment, filed in August, shows a stake that has fallen from 5.2% to 4.3% of the class. Under SEC rules, a holder who drops below 5% may exit without filing again, so the current position is as-last-disclosed and may have changed since August 18. Separately, the founder and CEO Andrew Feldman added 6.6 million shares in a transaction reported September 21, lifting his disclosed stake to 5.9% of shares. FMR (Fidelity) remains the largest disclosed holder at 25.7% of the class, though that figure has fallen sharply from 46.6%, suggesting meaningful distribution since the IPO. The insider flow on the sell side comes from CTO Sean Lie, who sold roughly $16.3 million of stock on September 25 under a pre-arranged 10b5-1 plan, a compensation-related programme rather than a discretionary signal.
Earnings history adds modest context. The last two quarterly releases each produced a next-day decline of around 1.6%, with five-day losses of 6.5% and 8.1% respectively. The next print is scheduled for November 12, 43 days away. With the stock down 8% on the week, that window will define whether the current short build was well-timed or premature.
What to watch: whether short interest continues to climb into the November earnings date, and whether borrow availability tightens again as it did in late August when availability nearly reached zero.
See the live data behind this article on ORTEX.
Open CBRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
